SEG-2022-01 Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sickle Cell Disease
- Sponsor
- Novartis
- Enrollment
- 376
- Locations
- 1
- Primary Endpoint
- Age at Index Date
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Age at Index Date
Time Frame: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Gender at Index Date
Time Frame: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Race
Time Frame: Day 1 of Year 2
Ethnicity
Time Frame: Day 1 of Year 2
Insurance Type at Index Date
Time Frame: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Number of Patients Categorized by Comorbidity
Time Frame: Baseline
Number of Patients who Received Long-acting Opioid Medication Before Starting Crizanlizumab
Time Frame: Baseline
Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy Before Starting Crizanlizumab Categorized by Duration of Therapy
Time Frame: Baseline
Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown
Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy After Starting Crizanlizumab Categorized by Duration of Therapy
Time Frame: Up to 1 year
Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown
Number of Patients by Type of Disease Modifying Therapy (DMT) Received Pre- and Post-index Date
Time Frame: Up to 2 years
Index date was defined as the date of the first crizanlizumab infusion. DMTs included: * Any SCD specific therapy * Hydroxyurea * Voxelotor * L-Glutamine * Other
Secondary Outcomes
- Number of Doses Received by Patients Who Continued and Discontinued Crizanlizumab Treatment(1 year)
- Number of SCD-related Hospitalizations and Emergency Department Visits Pre- and Post-index Date(Up to 2 years)
- Length of Stay of SCD-related Hospitalization Visits Pre- and Post-index Date(Up to 2 years)